102 related articles for article (PubMed ID: 8707769)
1. Tumor markers for breast cancer. Current utilities and future prospects.
Hayes DF
Hematol Oncol Clin North Am; 1994 Jun; 8(3):485-506. PubMed ID: 8707769
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers for breast cancer.
Hayes DF
Ann Oncol; 1993 Dec; 4(10):807-19. PubMed ID: 8117599
[TBL] [Abstract][Full Text] [Related]
3. Serum (circulating) tumor markers for breast cancer.
Hayes DF
Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor markers in breast cancer.
Tondini C; Hayes DF; Kufe DW
Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
[TBL] [Abstract][Full Text] [Related]
6. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in gynecological and breast cancer].
Jobo T; Sato R; Kuramoto H
Rinsho Byori; 2003 Dec; 51(12):1188-94. PubMed ID: 14743742
[TBL] [Abstract][Full Text] [Related]
8. Molecular prognostic factors for breast cancer metastasis and survival.
Esteva FJ; Sahin AA; Cristofanilli M; Arun B; Hortobagyi GN
Semin Radiat Oncol; 2002 Oct; 12(4):319-28. PubMed ID: 12382190
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
10. [CA15-3 tumor marker in early detection of breast cancer].
Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
[TBL] [Abstract][Full Text] [Related]
11. [Tumor markers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
[TBL] [Abstract][Full Text] [Related]
12. [Biomarkers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1021-6. PubMed ID: 15272579
[TBL] [Abstract][Full Text] [Related]
13. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
14. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
[TBL] [Abstract][Full Text] [Related]
16. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
Cheung KL; Graves CR; Robertson JF
Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
[TBL] [Abstract][Full Text] [Related]
17. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
[TBL] [Abstract][Full Text] [Related]
18. Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions.
Sneige N
Diagn Cytopathol; 2004 Mar; 30(3):158-65. PubMed ID: 14986295
[TBL] [Abstract][Full Text] [Related]
19. [Relative indicators for disease outcome in breast carcinoma].
Schnürch HG
Praxis (Bern 1994); 1998 Apr; 87(15):504-10. PubMed ID: 9608245
[TBL] [Abstract][Full Text] [Related]
20. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
